184 related articles for article (PubMed ID: 32253269)
1. Translating JAKs to Jakinibs.
Gadina M; Chisolm DA; Philips RL; McInness IB; Changelian PS; O'Shea JJ
J Immunol; 2020 Apr; 204(8):2011-2020. PubMed ID: 32253269
[TBL] [Abstract][Full Text] [Related]
2. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
[TBL] [Abstract][Full Text] [Related]
3. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark JD; Flanagan ME; Telliez JB
J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
[TBL] [Abstract][Full Text] [Related]
5. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.
Xu P; Shen P; Yu B; Xu X; Ge R; Cheng X; Chen Q; Bian J; Li Z; Wang J
Eur J Med Chem; 2020 Apr; 192():112155. PubMed ID: 32120325
[TBL] [Abstract][Full Text] [Related]
6. Janus kinases to jakinibs: from basic insights to clinical practice.
Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
[TBL] [Abstract][Full Text] [Related]
7. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
[TBL] [Abstract][Full Text] [Related]
11. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of Janus kinases.
Pesu M; Laurence A; Kishore N; Zwillich SH; Chan G; O'Shea JJ
Immunol Rev; 2008 Jun; 223():132-42. PubMed ID: 18613833
[TBL] [Abstract][Full Text] [Related]
13. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
[TBL] [Abstract][Full Text] [Related]
14. Advances in the discovery of selective JAK inhibitors.
Menet CJ; Rompaey LV; Geney R
Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors: Ten years after.
Spinelli FR; Meylan F; O'Shea JJ; Gadina M
Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
Liang X; Huang Y; Zang J; Gao Q; Wang B; Xu W; Zhang Y
Bioorg Med Chem; 2016 Jun; 24(12):2660-72. PubMed ID: 27137359
[TBL] [Abstract][Full Text] [Related]
17. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
18. Mucosal Epithelial Jak Kinases in Health and Diseases.
Kumar N; Kuang L; Villa R; Kumar P; Mishra J
Mediators Inflamm; 2021; 2021():6618924. PubMed ID: 33814980
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
20. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
